C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 14.85 USD 0.54% Market Closed
Market Cap: 360.3m USD
Have any thoughts about
CVRx Inc?
Write Note

CVRx Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CVRx Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
C
CVRx Inc
NASDAQ:CVRX
Income from Continuing Operations
-$41.2m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Income from Continuing Operations
$1.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
4%
Boston Scientific Corp
NYSE:BSX
Income from Continuing Operations
$1.8B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
Stryker Corp
NYSE:SYK
Income from Continuing Operations
$3.6B
CAGR 3-Years
24%
CAGR 5-Years
14%
CAGR 10-Years
19%
Abbott Laboratories
NYSE:ABT
Income from Continuing Operations
$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Income from Continuing Operations
$2.3B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

CVRx Inc
Glance View

Market Cap
359.4m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
11 USD
Overvaluation 26%
Intrinsic Value
Price
C

See Also

What is CVRx Inc's Income from Continuing Operations?
Income from Continuing Operations
-41.2m USD

Based on the financial report for Dec 31, 2023, CVRx Inc's Income from Continuing Operations amounts to -41.2m USD.

What is CVRx Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-43%

Over the last year, the Income from Continuing Operations growth was 1%. The average annual Income from Continuing Operations growth rates for CVRx Inc have been -43% over the past three years .

Back to Top